Brassicasteryl linoleate
Brassicasteryl linoleate is a cholinesterase inhibitor. Brassicasteryl linoleate inhibits acetylcholinesterase, butyrylcholinesterase and urease. Brassicasteryl linoleate inhibits lipid peroxidation. Brassicasteryl linoleate is applicable to research related to breast cancer, lung cancer and colon adenocarcinoma.
For research use only. We do not sell to patients.
- CAS No.: 73691-63-1
- Formula: C46H76O2
- Molecular Weight:661.09
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
|
AChE |
BChE |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MCF7 | IC50 |
67.20 μg/mL
|
Cytotoxic activity against human MCF-7 breast cancer cells assessed as reduction in cell viability by WST-1 assay.
Cytotoxic activity against human MCF-7 breast cancer cells assessed as reduction in cell viability by WST-1 assay.
|
40513695 |
| NCI-H1299 | IC50 |
92.24 μg/mL
|
Cytotoxic activity against human H1299 lung cancer cells assessed as reduction in cell viability by WST-1 assay.
Cytotoxic activity against human H1299 lung cancer cells assessed as reduction in cell viability by WST-1 assay.
|
40513695 |
| L929 | IC50 |
>200 μg/mL
|
Cytotoxic activity against murine L929 fibroblast cells assessed as reduction in cell viability by WST-1 assay, with no observed cytotoxic activity.
Cytotoxic activity against murine L929 fibroblast cells assessed as reduction in cell viability by WST-1 assay, with no observed cytotoxic activity.
|
40513695 |
| HeLa | IC50 |
>200 μg/mL
|
Cytotoxicity against human HeLa cervical cancer cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay.
Cytotoxicity against human HeLa cervical cancer cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay.
|
35218860 |
| HT-29 | IC50 |
73.2 μg/mL
|
Cytotoxicity against human HT29 colon adenocarcinoma cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay.
Cytotoxicity against human HT29 colon adenocarcinoma cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay.
|
35218860 |
| MCF7 | IC50 |
64.2 μg/mL
|
Cytotoxicity against human MCF7 breast cancer cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay.
Cytotoxicity against human MCF7 breast cancer cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay.
|
35218860 |
In Vitro
Brassicasteryl linoleate (compound 7) inhibits the viability of MCF-7 breast cancer cells with an IC50 of 67.20 μg/mL and H1299 lung cancer cells with an IC50 of 92.24 μg/mL, and is non-toxic to L929 murine fibroblast cells[1].
Brassicasteryl linoleate (compound 3) (48 h) exhibits weak cytotoxicity against HT29 and MCF7 cancer cell lines, no cytotoxicity against HeLa cancer cells, and weak toxicity against PDF fibroblast cells, with IC50 values of 73.2 µg/mL, 64.2 µg/mL, and 90.1 µg/mL, respectively[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 73691-63-1
-
Molecular Weight 661.09
-
Formula C46H76O2
-
SMILES
C[C@@]12[C@]3([H])[C@](CC=C1C[C@H](CC2)OC(CCCCCCC/C=C\C/C=C\CCCCC)=O)([H])[C@@]4([H])[C@](CC3)([C@@](CC4)([H])[C@H](C)/C=C/[C@H](C)C(C)C)C
-
Structure Classification
-
Initial Source
Sarcosphaera crassa
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Brassicasteryl linoleate Related Classifications
HY-186298 Related Classifications
Powered by Bioz